Market open

Avidity Biosciences/$RNA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Avidity Biosciences

Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.

Ticker

$RNA
Trading on

Industry

Biotechnology

Employees

391

RNA Metrics

BasicAdvanced
$3.6B
-
-$2.89
1.02
-
$3.6B
1.02
$49.81
$21.56
1.5M
15.735
15.607
0.208
0.477
-21.60%
-33.47%
304.836
2.5
2.5
-10.787
13.99%
-0.63%
5.33%
0.47%

What the Analysts think about RNA

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Avidity Biosciences stock.

RNA Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

RNA Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RNA

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs

What’s the current market cap for Avidity Biosciences stock?

Avidity Biosciences (RNA) has a market cap of $3.6B as of April 03, 2025.

What is the P/E ratio for Avidity Biosciences stock?

The price to earnings (P/E) ratio for Avidity Biosciences (RNA) stock is 0 as of April 03, 2025.

Does Avidity Biosciences stock pay dividends?

No, Avidity Biosciences (RNA) stock does not pay dividends to its shareholders as of April 03, 2025.

When is the next Avidity Biosciences dividend payment date?

Avidity Biosciences (RNA) stock does not pay dividends to its shareholders.

What is the beta indicator for Avidity Biosciences?

Avidity Biosciences (RNA) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.